First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study. // Journal of Hepatology. – URL: https://www.sciencedirect.com/science/article/pii/S0168827826029193?dgcid=rss_sd_all
First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study. Journal of Hepatology. https://www.sciencedirect.com/science/article/pii/S0168827826029193?dgcid=rss_sd_all
“First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study.” Journal of Hepatology.
@article{article107928,
title = {First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study},
journal = {Journal of Hepatology},
url = {https://www.sciencedirect.com/science/article/pii/S0168827826029193?dgcid=rss_sd_all}
}